Intrapleural heparin or heparin combined with human recombinant DNase is not effective in the treatment of empyema in a rabbit model

Respirology

Volumn 11, Issue 6, 2006, Pages 755-760

  Dikensoy, Oner ^a,b   Zhu, Zhiwen ^a,c   Na, Moon Jun ^a   Liao, Huai ^a   Donnelly, Edwin ^a   Light, Richard W ^a  

^a VANDERBILT UNIVERSITY   (United States)

^b GAZIANTEP UNIVERSITY   (Turkey)

^c SUN YAT SEN UNIVERSITY   (China)

Author keywords

Empyema; Heparin; Human recombinant DNase; Pleura; Pleural effusion

Indexed keywords

DORNASE ALFA; HEPARIN; LACTATE DEHYDROGENASE; SODIUM CHLORIDE;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; COMBINATION CHEMOTHERAPY; CONTROLLED STUDY; DISEASE MODEL; DRUG EFFICACY; EMPYEMA; GRAM NEGATIVE INFECTION; HISTOPATHOLOGY; INFECTION CONTROL; LEUKOCYTE COUNT; NONHUMAN; PASTEURELLA MULTOCIDA; PLEURA THICKENING; PRIORITY JOURNAL; RABBIT; STATISTICAL SIGNIFICANCE; TUBE;

ANIMALS; DEOXYRIBONUCLEASES; DISEASE MODELS, ANIMAL; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG THERAPY, COMBINATION; EMPYEMA; FIBRINOLYTIC AGENTS; HEPARIN; INJECTIONS; LEUKOCYTE COUNT; PLEURAL EFFUSION; RABBITS; RECOMBINANT PROTEINS;

EID: 33750088975     PISSN: 13237799     EISSN: 14401843     Source Type: Journal    
DOI: 10.1111/j.1440-1843.2006.00934.x     Document Type: Article

References (26)

1. Light RW. Pleural Diseases, 4th edn. Williams & Wilkins, Baltimore, MD, 2001.
2. Temes RT, Follis F, Kessler RM et al. Intrapleural fibrinolytics in management of empyema thoracis. Chest 1996; 110: 102-6.
3. Lim TK, Chin NK. Empirical treatment with fibrinolysis and early surgery reduces the duration of hospitalization in pleural sepsis. Eur. Respir. J. 1999; 13: 514-8.
4. Davies RJO, Traill ZC, Gleeson FV. Randomized controlled trial of intrapleural streptokinase in community acquired pleural infection. Thorax 1997; 52: 416-21.
5. Bouros D, Schiza S, Patsourakis G et al. Intrapleural streptokinase versus urokinase in the treatment of complicated parapneumonic effusion: a prospective, double-blind study. Am. J. Respir. Crit. Care Med. 1997; 155: 291-5.
6. Jerjes-Sanchez C, Ramirez-Rivera A, Elizalde JJ et al. Intrapleural fibrinolysis with streptokinase as an adjunctive treatment in hemothorax and empyema: a multicenter trial. Chest 1996; 109: 1514-9.
7. Laisaar T, Puttsepp E, Laisaar V. Early administration of intrapleural streptokinase in the treatment of multiloculated pleural effusion and pleural empyemas. Thorac. Cardiovasc. Surg. 1996; 44: 252-6.
8. Moulton JS, Benkert RE, Weisiger KH et al. Treatment of complicated pleural fluid collections with image-guided drainage and intracavitary urokinase. Chest 1995; 108: 1252-9.
9. Maskell NA, Davies CW, Nunn AJ et al. U.K. Controlled trial of intrapleural streptokinase for pleural infection. N. Engl. J. Med. 2005; 352: 865-74.
10. Light RW, Nguyen T, Mulligan ME et al. The in vitro efficacy of varidase versus streptokinase or urokinase for liquefying thick purulent exudative material from loculated empyema. Lung 2000; 178: 13-8.
11. Erkan L, Fýndýk S, Uzun O et al. A new radiologic appearance of pulmonary thromboembolism: multiloculated pleural effusions. Chest 2004; 126: 298-302.
12. Sasse SA, Causing LA, Mulligan ME, Light RW. Serial pleural fluid analysis in a new experimental model of empyema. Chest 1996; 109: 1043-8.
13. Sasse S, Nguyen TK, Mulligan M et al. The effects of early chest tube placement on empyema resolution. Chest 1997; 111: 1679-83.
14. Light RW, Cheng DS, Lee YCG et al. A single intrapleural injection of transforming growth factor beta-2 produces an excellent pleurodesis in rabbits. Am. J. Respir. Crit. Care Med. 2000; 162: 98-104.
15. Lee YCG, Teixeira LR, Devin CJ et al. Transforming Growth Factor-2 induces pleurodesis significantly faster than talc. Am. J. Respir. Crit. Care Med. 2000; 163: 640-4.
16. Tillet WS, Sherry S, Read CT. The use of streptokinase-streptodornase in the treatment of postpneumonic empyema. J. Thorac. Surg. 1951; 21: 275-97.
17. Crabbe SJ, Cloninger CC. Tissue plasminogen activator: a new thrombolytic agent. Clin. Pharm. 1987; 6: 373-86. Review. Erratum in: Clin. Pharm. 1987; 6: 9.
18. Stevens A, Tobias JD. Tissue plasminogen activator as an adjunctive therapy of empyema in a child. J. Intensive Care Med. 2001; 16: 287-9.
19. Bishop NB, Pon S, Ushay M et al. Alteplase in the treatment of complicated parapneumonic effusion: a case report. Pediatrics 2003; 111: e188-e190.
20. Ray RL, Berkenbosh JW, Russo P et al. Tissue plasminogen activator as a adjunctive therapy of empyema in pediatric patients. J. Intensive Care Med. 2004; 19: 44-50.
21. Simpson G, Roomes D, Heron M. Effects of streptokinase and deoxyribonuclease on viscosity of human surgical and empyema pus. Chest 2000; 117: 1728-33.
22. Zhu Z, Hawthorne ML, Guo Y et al. Tissue plasminogen activator combined with human recombinant DNase is effective therapy for empyema in a rabbit model. Chest 2006; 129: 1577-83.
23. Strange C, Baumann MH, Sahn SA et al. Effects of intrapleural heparin or urokinase on the extent of tetracycline induced pleural disease. Am. J. Respir. Crit. Care Med. 1995; 151: 508-15.
24. Ekingen G, Guvenc BH, Sozubir S et al. Fibrinolytic treatment of complicated pediatric thoracic empyemas with intrapleural streptokinase. Eur. J. Cardiothorac. Surg. 2004; 26: 503-7.
25. Yao CT, Wu JM, Liu CC et al. Treatment of complicated parapneumonic pleural effusion with intrapleural streptokinase in children. Chest 2004; 125: 566-71.
26. Watanabe S, Suzuki T, Shizawa S et al. Heparin accelerates pulmonary artery development in neonate rabbits. Tohoku J. Exp. Med. 2005; 207: 171-9.